Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aurion Biotech

Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
From Aurion Biotech
Via Business Wire
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer
From Aurion Biotech
Via Business Wire
Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer and Eris P. Jordan, O.D., as Chief Development Officer
From Aurion Biotech
Via Business Wire
Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea
From Aurion Biotech
Via Business Wire
Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum
From Aurion Biotech
Via Business Wire
Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001
From Aurion Biotech
Via Business Wire
Aurion Biotech CEO Greg Kunst Named Ernst & Young 2024 Entrepreneur of the Year Mountain West Region
From Aurion Biotech
Via Business Wire
Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial
From Aurion Biotech
Via Business Wire
Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Aurion Biotech
Via Business Wire
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
From Aurion Biotech
Via Business Wire
Greg Kunst, CEO of Aurion Biotech, Receives Healthcare Leadership Award from Puget Sound Business Journal
From Aurion Biotech
Via Business Wire
Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By BioTech Breakthrough
From Aurion Biotech
Via Business Wire
Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial
From Aurion Biotech
Via Business Wire
Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Aurion Biotech
Via Business Wire
Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application
From Aurion Biotech
Via Business Wire
Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer
From Aurion Biotech
Via Business Wire
Aurion Biotech Expands Its Leadership Team
From Aurion Biotech
Via Business Wire
Aurion Biotech Wins Prestigious Prix Galien Startup Award
From Aurion Biotech
Via Business Wire
Aurion Biotech Nominated for Prix Galien Startup Award
From Aurion Biotech
Via Business Wire
Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
From Aurion Biotech
Via Business Wire
Aurion Biotech Raises $120 Million from Deerfield Management, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures
From Aurion Biotech
Via Business Wire
Aurion Biotech Announces Medical Advisory Board
From Aurion Biotech
Via Business Wire
Aurion Biotech Announces Strategic Investments in Manufacturing
From Aurion Biotech
Via Business Wire
Daniela Drago Joins Aurion Biotech as Chief Regulatory Officer
From Aurion Biotech
Via Business Wire
Aurion Biotech Announces IOTA Cell Therapy Trial
From Aurion Biotech
Via Business Wire
Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Board
From Aurion Biotech
Via Business Wire
Aurion Biotech Names Edward Holland, MD, Chief Medical Advisor
From Aurion Biotech
Via Business Wire
Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotech
From Aurion Biotech
Via Business Wire
Greg Kunst Appointed CEO of Aurion Biotech
From Aurion Biotech
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.